WHAT IS FEMALE SEXUAL DYSFUNCTION?
Sexual dysfunction is defi ned as a persistent or recurrent sexual problem that causes marked distress or interpersonal diffi culty. The 2013 Diagnostic and Statistical Manual of Mental Disorders (1) classifi es female sexual dysfunction (FSD) into three domains: female sexual interest/arousal disorder; female orgasmic disorder; and genito-pelvic pain/penetration disorder. Female sexual interest/arousal disorder occurs when a woman experiences persistent or recurrent inability to attain sexual arousal, or to maintain arousal until the completion of a sexual activity. (1) This disorder can also refer to an inadequate lubrication-swelling response that is normally present during arousal and sexual activity. Female orgasmic disorder occurs when a woman either cannot reach orgasm or has trouble reaching orgasm even after ample sexual stimulation. This disorder can be primary, or secondary due to ageing. Genito-pelvic pain/penetration disorder, commonly known as vaginismus, is diagnosed when a patient experiences persistent or recurrent diffi culties with one or more of the following for a minimum duration of six months: (a) vaginal penetration during intercourse; (b) marked vulvovaginal or pelvic pain during vaginal intercourse or penetration attempts; (c) marked fear or anxiety about vulvovaginal or pelvic pain in anticipation of, during, or as a result of vaginal penetration; and (d) marked tensing or tightening of the pelvic fl oor muscles during attempted vaginal penetration.
The worldwide prevalence of FSD ranges from 27% to 70%. (2) (3) (4) FSD is associated with various demographic characteristics, including age and educational level. Sociocultural barriers, taboos and misconceptions make the estimation of prevalence diffi cult. 
HOW RELEVANT IS THIS TO MY PRACTICE?
Combined oral contraceptives (COCs) are an affordable and reversible form of contraception. It is the third most popular contraceptive method, after female sterilisation and intrauterine devices, as it provides a high degree of contraceptive effi cacy with an excellent safety profi le and is a reversible method of birth control that is available throughout the world. (5) The use of COCs worldwide in women of reproductive age was reported to be around 14% in 2015. (5) While there are existing guidelines from the World Health Organization (WHO) and the United States' Centers for Disease Control and Prevention (CDC) on the use of COCs, (6, 7) they do not mention their effect on sexuality, even though there is evidence to suggest that older-generation COCs can cause female sexual dysfunction. (8) 
Starting patients on combined oral contraceptive pills
Prior to starting COCs, the physician should evaluate the patient for contraindications and risks associated with COCs by conducting a thorough history and physical examination (Table I) . After excluding any contraindications, the physician will recommend the method in which COCs should be started based on the patient's last menstrual period and other associated conditions, such as whether she is starting contraception postpartum or switching from another contraceptive method (Fig. 1 
Important considerations when prescribing COCs to women of reproductive age
It is important to consider the effects of COCs on sexual function when prescribing them to women of reproductive age. WHO and CDC have established good practice guidance on how to assess women before prescribing COCs. (6, 7) However, neither recommends the screening and assessment of sexual function, which we consider to be important. First, physicians should screen patients for pre-existing FSD, and inform them of the possible sexual side effects of COCs before prescribing them. (8) Second, COCs that contain drospirenone and ethinylestradiol or gestodene and ethinylestradiol are preferred choices for women who are concerned about sexual dysfunction, as they are less likely to cause FSD. (8) Third, patients who are taking COCs need regular review; during clinic visits, physicians should inquire about any sexual side effects, such as decreased sexual desire and dyspareunia. Fourth, in adolescents, a non-COC option for treating acne is preferred over COCs; however, if COCs are prescribed to this age group, the treatment duration should not exceed two years. 
Recommended follow-up
There is currently no recommended interval for follow-up after the initiation of COCs. However, in view of some of the effects of COCs, we recommend that patients should be followed up at one month, three months and six months after initiation of COCs, and yearly thereafter. During the follow-up visit, the physician should: (a) assess for compliance and pattern of withdrawal bleeding; (b) assess for any adverse reactions to the medications such as headache; (c) assess for sexual function, particularly in the domains of sexual desire and dyspareunia; (d) measure blood pressure; and (e) calculate the body mass index. 
History of VTE Do not use

Sexual history
Assess sexual function, especially in the domains of desire and dyspareunia
Older-generation COCs have been associated with sexual dysfunction in women; (8) sexual function should be assessed prior to starting COCs and reviewed regularly
Physical examination Recommendation
Blood pressure Systolic ≥ 160 mmHg or diastolic ≥ 100 mmHg Systolic 140-159 mmHg or diastolic 90-99 mmHg or adequately controlled hypertension Do not use Avoid if possible; however, adequately controlled hypertension lowers the cardiovascular risk of COC (6) 
BMI
Increased BMI is not a contradiction to COC use, but there is an increased risk of VTE in those with increased BMI
Pelvic examination
Not necessary, as it does not detect any condition that is contraindicated for COC use
Tests Recommendation
No tests are recommended prior to starting.
BMI: body mass index; IHD: ischaemic heart disease; VTE: venous thromboembolism TAKE HOME MESSAGES (1) Visit the SMJ website: http://www.smj.org.sg/current-issue and select the appropriate set of questions. (2) Provide your name, email address and MCR number. (3) Select your answers and click "Submit".
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(1) Answers will be published online in the SMJ August 2017 issue. 
